However, challenges to exploiting these vulnerabilities include thrombocytopenia caused by BCLXL inhibition, and the possible requirement for high concentrations of MCL1 antagonists, whose toxicity profile remains to be established. Here, BCL2L1 is linked to Thrombocytopenia.